Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.
| Drug | TSG | SLP (drug target) | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | # |
|---|---|---|---|---|---|---|---|---|---|---|
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | CDK12 | NTRK1 | 4 | |||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | CDK12 | NTRK1 | 4 | |||||||
| trastuzumab emtansine | CDK12 | ERBB2 | 7 | |||||||
| tucatinib | CDK12 | ERBB2 | 7 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | CDK12 | ERBB2 | 3 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | CDK12 | NTRK1 | 3 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | CDK12 | WEE1 | 3 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | CDK12 | CSK | 3 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | CDK12 | LCK | 3 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | CDK12 | PIK3CD | 3 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | CDK12 | AKT2 | 3 | |||||||
| afatinib | CDK12 | ERBB2 | 3 | |||||||
| futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan | CDK12 | TOP1 | 3 | |||||||
| lurbinectedin, irinotecan | CDK12 | TOP1 | 3 | |||||||
| mrtx849, pembrolizumab, cetuximab, afatinib | CDK12 | ERBB2 | 3 | |||||||
| lapatinib | CDK12 | ERBB2 | 7 | |||||||
| sacituzumab govitecan | CDK12 | TOP1 | 7 | |||||||
| topotecan | CDK12 | TOP1 | 7 | |||||||
| trastuzumab deruxtecan | CDK12 | TOP1 | 5 | |||||||
| adavosertib, radiation therapy | CDK12 | WEE1 | 2 | |||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | CDK12 | ERBB2 | 2 | |||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | CDK12 | IGF1R | 2 | |||||||
| alendronate, etidronate, ibandronate, risedronate, raloxifene | CDK12 | FDPS | 2 | |||||||
| alvocidib, paclitaxel | CDK12 | CDK8 | 2 | |||||||
| alvocidib, paclitaxel | CDK12 | CDK9 | 2 | |||||||
| alvocidib, paclitaxel | CDK12 | CDK5 | 2 | |||||||
| apatinib, irinotecan | CDK12 | TOP1 | 2 | |||||||
| asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan | CDK12 | TOP1 | 2 | |||||||
| asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine | CDK12 | TOP1 | 2 | |||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | CDK12 | CSK | 2 | |||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | CDK12 | LCK | 2 | |||||||
| bryostatin 1, paclitaxel | CDK12 | PRKCA | 2 | |||||||
| cetuximab, cisplatin, irinotecan, radiation therapy, surgery | CDK12 | TOP1 | 2 | |||||||
| cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study | CDK12 | IGF1R | 2 | |||||||
| cixutumumab, laboratory biomarker analysis, paclitaxel, pharmacological study | CDK12 | IGF1R | 2 | |||||||
| eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab | CDK12 | ERBB2 | 2 | |||||||
| entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib | CDK12 | ERBB2 | 2 | |||||||
| entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib | CDK12 | NTRK1 | 2 | |||||||
| inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide | CDK12 | TOP1 | 2 | |||||||
| irinotecan, capecitabine | CDK12 | TOP1 | 2 | |||||||
| irinotecan, docetaxel | CDK12 | TOP1 | 2 | |||||||
| ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab | CDK12 | TOP1 | 2 | |||||||
| nintedanib | CDK12 | LCK | 2 | |||||||
| nintedanib, pembrolizumab | CDK12 | LCK | 2 | |||||||
| olaparib | CDK12 | PARP3 | 2 | |||||||
| pembrolizumab, paclitaxel, docetaxel, irinotecan | CDK12 | TOP1 | 2 | |||||||
| radiotherapy targeted to the primary lesion, radiotherapy targeted to the metastatic lesions, anti-pd-1 monoclonal antibody, trastuzumab, chemotherapy, r0 total/subtotal gastrectomy with d2 lymphadenectomy, metastasectomy, local ablative therapies | CDK12 | ERBB2 | 2 | |||||||
| regorafenib | CDK12 | NTRK1 | 2 | |||||||
| regorafenib, laboratory biomarker analysis | CDK12 | NTRK1 | 2 | |||||||
| rubitecan | CDK12 | TOP1 | 2 | |||||||
| trastuzumab | CDK12 | ERBB2 | 2 | |||||||
| trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy | CDK12 | ERBB2 | 2 | |||||||
| trastuzumab, tipifarnib | CDK12 | ERBB2 | 2 | |||||||
| entrectinib | CDK12 | NTRK1 | 7 | |||||||
| rosuvastatin | CDK12 | HMGCR | 7 | |||||||
| 18f-fluoromisonidazole, cediranib maleate, laboratory biomarker analysis, olaparib, positron emission tomography | CDK12 | PARP3 | 1 | |||||||
| 2b3-101, trastuzumab, 2b3-101 60 mg/m2 every 4 weeks, 2b3-101 50 mg/m2 every 3 weeks | CDK12 | ERBB2 | 1 | |||||||
| 5 fluorouracil, leucovorin, irinotecan, oxaliplatin | CDK12 | TOP1 | 1 | |||||||
| 5-fu, leucovorin, docetaxel, oxaliplatin (flot), trastuzumab, post-operative treatment trastuzumab mono therapy | CDK12 | ERBB2 | 1 | |||||||
| 9-ing-41, gemcitabine - 21 day cycle, doxorubicin., lomustine, carboplatin., nab paclitaxel., paclitaxel., gemcitabine - 28 day cycle, irinotecan | CDK12 | TOP1 | 1 | |||||||
| abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf | CDK12 | TOP1 | 1 | |||||||
| adavosertib | CDK12 | WEE1 | 1 | |||||||
| adavosertib, laboratory biomarker analysis, pharmacological study, radiation therapy | CDK12 | WEE1 | 1 | |||||||
| adavosertib, radiation therapy, temozolomide | CDK12 | WEE1 | 1 | |||||||
| adjuvant therapy, temozolomide, valproic acid, radiation therapy | CDK12 | CDKN1A | 1 | |||||||
| adriamycin, cyclophosphamide, vindesine, valproic acid | CDK12 | CDKN1A | 1 | |||||||
| afatinib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging | CDK12 | ERBB2 | 1 | |||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | CDK12 | PARP3 | 1 | |||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | CDK12 | ERBB2 | 1 | |||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | CDK12 | CSK | 1 | |||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | CDK12 | LCK | 1 | |||||||
| afatinib, docetaxel, radiation therapy | CDK12 | ERBB2 | 1 | |||||||
| afatinib, gefitinib | CDK12 | ERBB2 | 1 | |||||||
| afatinib, irinotecan | CDK12 | ERBB2 | 1 | |||||||
| afatinib, irinotecan | CDK12 | TOP1 | 1 | |||||||
| aldesleukin, therapeutic autologous lymphocytes, zoledronic acid | CDK12 | FDPS | 1 | |||||||
| aldoxorubicin, topotecan | CDK12 | TOP1 | 1 | |||||||
| alvocidib, docetaxel | CDK12 | CDK8 | 1 | |||||||
| alvocidib, docetaxel | CDK12 | CDK9 | 1 | |||||||
| alvocidib, docetaxel | CDK12 | CDK5 | 1 | |||||||
| alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis | CDK12 | CDK8 | 1 | |||||||
| alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis | CDK12 | CDK9 | 1 | |||||||
| alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis | CDK12 | CDK5 | 1 | |||||||
| aminolevulinic acid | CDK12 | ALAD | 1 | |||||||
| aminolevulinic acid, surgical resection | CDK12 | ALAD | 1 | |||||||
| amrubicin, topotecan | CDK12 | TOP1 | 1 | |||||||
| andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel | CDK12 | TOP1 | 1 | |||||||
| arsenic trioxide | CDK12 | CDKN1A | 1 | |||||||
| arsenic trioxide, radiation therapy | CDK12 | CDKN1A | 1 | |||||||
| arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy | CDK12 | CDKN1A | 1 | |||||||
| at-101, topotecan | CDK12 | TOP1 | 1 | |||||||
| atorvastatin, temozolomide, radiotherapy | CDK12 | HMGCR | 1 | |||||||
| avastin, temozolomide, irinotecan | CDK12 | TOP1 | 1 | |||||||
| avastin, temozolomide, radiation therapy (xrt), irinotecan | CDK12 | TOP1 | 1 | |||||||
| avelumab, irinotecan, paclitaxel, best supportive care (bsc) | CDK12 | TOP1 | 1 | |||||||
| azd0901, 5-fluorouracil, leucovorin, l-leucovorin, irinotecan, nanoliposomal irinotecan, gemcitabine | CDK12 | TOP1 | 1 | |||||||
| azd1775, olaparib | CDK12 | PARP3 | 1 | |||||||
| azenosertib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, multigated acquisition scan, trastuzumab deruxtecan | CDK12 | TOP1 | 1 | |||||||
| bbi608, nab-paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, fluorouracil, mm-398 | CDK12 | TOP1 | 1 | |||||||
| bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil | CDK12 | TOP1 | 1 | |||||||
| berzosertib, computed tomography assisted biopsy, endoscopic biopsy, irinotecan, magnetic resonance imaging | CDK12 | TOP1 | 1 | |||||||
| berzosertib, sacituzumab govitecan | CDK12 | TOP1 | 1 | |||||||
| bevacizumab [avastin], irinotecan, temozolomide | CDK12 | TOP1 | 1 | |||||||
| bevacizumab, cediranib, cediranib maleate, olaparib | CDK12 | PARP3 | 1 | |||||||
| bevacizumab, dasatinib, placebo | CDK12 | CSK | 1 | |||||||
| bevacizumab, dasatinib, placebo | CDK12 | LCK | 1 | |||||||
| bevacizumab, irinotecan | CDK12 | TOP1 | 1 | |||||||
| bevacizumab, irinotecan, dynamic contrast-enhanced magnetic resonance imaging | CDK12 | TOP1 | 1 | |||||||
| bevacizumab, temozolomide, radiation therapy (xrt), topotecan | CDK12 | TOP1 | 1 | |||||||
| bi 764532, topotecan, single agent chemotherapy | CDK12 | TOP1 | 1 | |||||||
| biopsy, biospecimen collection, ceralasertib, computed tomography, echocardiography, multigated acquisition scan, positron emission tomography, trastuzumab deruxtecan | CDK12 | TOP1 | 1 | |||||||
| biopsy, biospecimen collection, computed tomography, copanlisib, magnetic resonance imaging | CDK12 | PIK3CD | 1 | |||||||
| biopsy, biospecimen collection, computed tomography, endoscopic ultrasound, fluorouracil, irinotecan, leucovorin, lymph node biopsy, magnetic resonance imaging, oxaliplatin, pembrolizumab, photodynamic therapy, positron emission tomography, questionnaire administration, verteporfin | CDK12 | TOP1 | 1 | |||||||
| biopsy, biospecimen collection, computed tomography, larotrectinib, magnetic resonance imaging | CDK12 | NTRK1 | 1 | |||||||
| biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, olaparib | CDK12 | PARP3 | 1 | |||||||
| biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, olaparib, pembrolizumab | CDK12 | PARP3 | 1 | |||||||
| biopsy, biospecimen collection, copanlisib, radiologic examination | CDK12 | PIK3CD | 1 | |||||||
| biopsy, biospecimen collection, echocardiography, pertuzumab, radiologic examination, trastuzumab | CDK12 | ERBB2 | 1 | |||||||
| biospecimen collection, computed tomography, core biopsy, fluorouracil, irinotecan, leucovorin, leucovorin calcium, oxaliplatin, quemliclustat, zimberelimab | CDK12 | TOP1 | 1 | |||||||
| biospecimen collection, computed tomography, magnetic resonance imaging, olaparib, placebo administration | CDK12 | PARP3 | 1 | |||||||
| bl-b01d1, irinotecan, paclitaxel, docetaxel | CDK12 | TOP1 | 1 | |||||||
| bl-b01d1, topotecan | CDK12 | TOP1 | 1 | |||||||
| bnt327 dose level 1 (dl1), bnt327 dose level 2 (dl2), etoposide, carboplatin, paclitaxel, topotecan | CDK12 | TOP1 | 1 | |||||||
| bortezomib, irinotecan | CDK12 | TOP1 | 1 | |||||||
| byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab | CDK12 | LCK | 1 | |||||||
| camrelizumab, docetaxel, irinotecan | CDK12 | TOP1 | 1 | |||||||
| camrelizumab, irinotecan, paclitaxel, paclitaxel-albumin, docetaxel, anlotinib | CDK12 | TOP1 | 1 | |||||||
| capecitabine, fluorouracil, laboratory biomarker analysis, pharmacological study, stereotactic body radiation therapy, zoledronic acid | CDK12 | FDPS | 1 | |||||||
| capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab | CDK12 | PARP3 | 1 | |||||||
| capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab | CDK12 | ERBB2 | 1 | |||||||
| capecitabine, oxaliplatin, irinotecan | CDK12 | TOP1 | 1 | |||||||
| capivasertib | CDK12 | AKT2 | 1 | |||||||
| carboplatin, irinotecan | CDK12 | TOP1 | 1 | |||||||
| carboplatin, laboratory biomarker analysis, paclitaxel, quality-of-life assessment, radiation therapy, therapeutic conventional surgery, trastuzumab | CDK12 | ERBB2 | 1 | |||||||
| carboxylesterase-expressing allogeneic neural stem cells, irinotecan, irinotecan hydrochloride, laboratory biomarker analysis, pharmacological study | CDK12 | TOP1 | 1 | |||||||
| ceralasertib, olaparib, durvalumab | CDK12 | PARP3 | 1 | |||||||
| cetuximab, bevacizumab, irinotecan | CDK12 | TOP1 | 1 | |||||||
| cetuximab, irinotecan, oxaliplatin, uft | CDK12 | TOP1 | 1 | |||||||
| cetuximab, trastuzumab | CDK12 | ERBB2 | 1 | |||||||
| cisplatin, 5-fluorouracil or capecitabine, trastuzumab, pertuzumab, gastrectomy | CDK12 | ERBB2 | 1 | |||||||
| cisplatin, fluorouracil, gemcitabine, irinotecan, leucovorin, nab-paclitaxel, oxaliplatin, radiation therapy | CDK12 | TOP1 | 1 | |||||||
| cisplatin, gleevec™, irinotecan | CDK12 | TOP1 | 1 | |||||||
| cisplatin, irinotecan, capecitabine | CDK12 | TOP1 | 1 | |||||||
| cobimetinib, olaparib, onvansertib, azenosertib, saruparib, tremelimumab | CDK12 | PARP3 | 1 | |||||||
| cytoreductive surgery, perifosine, temsirolimus | CDK12 | PRKCA | 1 | |||||||
| dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride | CDK12 | CSK | 1 | |||||||
| dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride | CDK12 | LCK | 1 | |||||||
| dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method | CDK12 | CSK | 1 | |||||||
| dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method | CDK12 | LCK | 1 | |||||||
| dasatinib, laboratory biomarker analysis, physiologic testing | CDK12 | CSK | 1 | |||||||
| dasatinib, laboratory biomarker analysis, physiologic testing | CDK12 | LCK | 1 | |||||||
| dasatinib, mfolfox6 | CDK12 | CSK | 1 | |||||||
| dasatinib, mfolfox6 | CDK12 | LCK | 1 | |||||||
| dasatinib, pharmacological study | CDK12 | CSK | 1 | |||||||
| dasatinib, pharmacological study | CDK12 | LCK | 1 | |||||||
| dasatinib, temozolomide, placebo, radiation therapy | CDK12 | CSK | 1 | |||||||
| dasatinib, temozolomide, placebo, radiation therapy | CDK12 | LCK | 1 | |||||||
| db-1310, trastuzumab, osimertinib | CDK12 | ERBB2 | 1 | |||||||
| digoxin, 5fluorouracil, calcium leucovorin, irinotecan, oxaliplatin | CDK12 | TOP1 | 1 | |||||||
| disitamab vedotin, tucatinib | CDK12 | ERBB2 | 1 | |||||||
| docetaxel, leucovorin, fluorouracil, cisplatin, docetaxel, cisplatin, fluorouracil, neulasta, or neupogen, docetaxel, leukvorin, flurouracil, cisplatin, trastuzumab | CDK12 | ERBB2 | 1 | |||||||
| docetaxel, oxaliplatin, capecitabine, trastuzumab | CDK12 | ERBB2 | 1 | |||||||
| doxorubicin, cisplatin, 5-fluorouracil | CDK12 | TOP1 | 1 | |||||||
| durvalumab, olaparib | CDK12 | PARP3 | 1 | |||||||
| durvalumab, olaparib, cediranib | CDK12 | PARP3 | 1 | |||||||
| durvalumab, oxaliplatin, irinotecan, calcium folinate (leucovorin), fluorouracil, pegylated g-csf | CDK12 | TOP1 | 1 | |||||||
| edotecarin, temozolomide, carmustine (bcnu), lomustine (ccnu) | CDK12 | TOP1 | 1 | |||||||
| ep0057, olaparib | CDK12 | PARP3 | 1 | |||||||
| evorpacept (alx148), trastuzumab, ramucirumab, paclitaxel | CDK12 | ERBB2 | 1 | |||||||
| fluorouracil (5-fu), capecitabine, durvalumab, oxaliplatin, trastuzumab, trastuzumab deruxtecan, cisplatin, pembrolizumab, volrustomig, rilvegostomig | CDK12 | ERBB2 | 1 | |||||||
| fluorouracil (5-fu), capecitabine, durvalumab, oxaliplatin, trastuzumab, trastuzumab deruxtecan, cisplatin, pembrolizumab, volrustomig, rilvegostomig | CDK12 | TOP1 | 1 | |||||||
| fluorouracil, irinotecan sucrosofate, laboratory biomarker analysis, leucovorin calcium, rucaparib | CDK12 | PARP3 | 1 | |||||||
| fluorouracil, irinotecan, irinotecan hydrochloride, leucovorin, leucovorin calcium, nivolumab, oxaliplatin, therapeutic conventional surgery | CDK12 | TOP1 | 1 | |||||||
| fluorouracil, leucovorin calcium, oxaliplatin, irinotecan, nivolumab, magnetic resonance imaging, computed tomography, biospecimen collection, questionnaire administration | CDK12 | TOP1 | 1 | |||||||
| fluorouracil, oxaliplatin, irinotecan | CDK12 | TOP1 | 1 | |||||||
| gemcitabine, nab-paclitaxel, irinotecan, intensity-modulated radiation therapy (imrt) | CDK12 | TOP1 | 1 | |||||||
| gemcitabine, oxaliplatin, imatinib | CDK12 | NTRK1 | 1 | |||||||
| gemcitabine, taxotere, xeloda, cisplatin, irinotecan | CDK12 | TOP1 | 1 | |||||||
| ifinatamab deruxtecan, docetaxel, paclitaxel, irinotecan | CDK12 | TOP1 | 1 | |||||||
| imab362, zoledronic acid, interleukin-2 (1 million iu), interleukin-2 (3 million iu) | CDK12 | FDPS | 1 | |||||||
| imatinib, irinotecan, carboplatin | CDK12 | NTRK1 | 1 | |||||||
| imatinib, irinotecan, carboplatin | CDK12 | TOP1 | 1 | |||||||
| insulin degludec, insulin glargine | CDK12 | IGF1R | 1 | |||||||
| irinotecan hydrochloride liposome injection, topotecan | CDK12 | TOP1 | 1 | |||||||
| irinotecan, 5-fluorouracil, leucovorin | CDK12 | TOP1 | 1 | |||||||
| irinotecan, bevacizumab, fdopa-pet/mri imaging | CDK12 | TOP1 | 1 | |||||||
| irinotecan, carboplatin, bevacizumab | CDK12 | TOP1 | 1 | |||||||
| irinotecan, carboplatin, bevacizumab, radiation | CDK12 | TOP1 | 1 | |||||||
| irinotecan, carboplatin, bevacizumab, radiation therapy | CDK12 | TOP1 | 1 | |||||||
| irinotecan, cisplatin, simvastatin | CDK12 | TOP1 | 1 | |||||||
| irinotecan, cisplatin, simvastatin | CDK12 | HMGCR | 1 | |||||||
| irinotecan, ibi343, paclitaxel | CDK12 | TOP1 | 1 | |||||||
| irinotecan, leucovorin, 5-fluorouracil, docetaxel, cisplatin, leucovorin, 5-fluorouracil | CDK12 | TOP1 | 1 | |||||||
| irinotecan, lurbinectedin, irinotecan, topotecan, lurbinectedin | CDK12 | TOP1 | 1 | |||||||
| irinotecan, radiation therapy | CDK12 | TOP1 | 1 | |||||||
| irinotecan, ramucirumab, blood for angiome profiling, blood for cfdna | CDK12 | TOP1 | 1 | |||||||
| kc1036, irinotecan, docetaxel, s-1 | CDK12 | TOP1 | 1 | |||||||
| laboratory biomarker analysis, lapatinib, lapatinib ditosylate, pharmacological study, therapeutic conventional surgery | CDK12 | ERBB2 | 1 | |||||||
| laboratory biomarker analysis, linsitinib, pharmacological study, topotecan hydrochloride | CDK12 | IGF1R | 1 | |||||||
| laboratory biomarker analysis, perifosine, temsirolimus, therapeutic conventional surgery | CDK12 | PRKCA | 1 |